MedTrace Logo

To Evaluate the Clinical Efficacy and Safety of Recombinant Human Interferon ω Spray in Treatment of Viral Upper Respiratory Tract Infection in Children

NCT05859984 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 345

Last updated 2023-05-16

No results posted yet for this study

Summary

To evaluate the clinical efficacy and safety of recombinant human interferon ω spray in treatment of viral upper respiratory tract infection in children aged by 3-12 years, and to explore the appropriate usage and dosage of the drug in treatment of upper respiratory tract infection caused by viruses.

Conditions

  • Viral Upper Respiratory Tract Infection

Interventions

DRUG

recombinant human interferon ω spray

8 ml/bottle（contain 2 million IU recombinant human interferon ω）

Sponsors & Collaborators

  • The General Hospital of Central Theater Command

    collaborator OTHER

  • The General Hospital of Northern Theater Command

    collaborator OTHER

  • Seventh Medical Center of PLA General Hospital

    lead OTHER

Principal Investigators

  • Zhichuan Feng, M.M · Seventh Medical Center of PLA General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-31
Primary Completion
2024-05-31
Completion
2024-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05859984 on ClinicalTrials.gov